Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
Novo Nordisk A/S Bagsværd, Denmark, 31 July 2026 – Novo Nordisk today announced headline results from the ZEUS cardiovascular…
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
Novo Nordisk A/S Bagsværd, Denmark, 31 July 2026 – Novo Nordisk today announced headline results from the ZEUS cardiovascular…
Novo Nordisk POSEIDON Data Highlights Residual Inflammatory Risk And New Opportunity
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
Novo Nordisk POSEIDON Data Highlights Residual Inflammatory Risk And New Opportunity
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke
The Novo Nordisk study POSEIDON – including 18,904 patients across 18 countries – showed that cardiovascular (CV) inflammation…
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke
Novo Nordisk A/S The Novo Nordisk study POSEIDON – including 18,904 patients across 18 countries – showed that…
Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke
Novo Nordisk A/S The Novo Nordisk study POSEIDON – including 18,904 patients across 18 countries – showed that…